Erytech strengthens leadership, appointing CSO and CBO

French biotech firm Erytech Pharma (Euronext Paris: ERYP) today announced the appointments of Dr Alexander Scheer, as the company’s chief scientific officer and Jean-Sébastien Cleiftie, as chief business officer.

“We are delighted to welcome Alexander and Jean-Sébastien to the Erytech leadership team as they both bring invaluable experience from cross-functional areas of the life science industry,” commented Gil Beyen, chief executive and chairman of Erytech Pharma. “Alexander brings a wealth of knowledge in leading global R&D and drug discovery across multiple disciplines and several therapeutic areas, while Jean-Sébastien’s deep expertise in biopharmaceutical business development and financial valuation will be instrumental to Erytech as we continue to diversify our programs and address unmet medical needs of patients,” he added.

Dr Scheer has over 15 years of experience in R&D and the life science industry. Prior to joining Erytech, he served as the head of research at Pierre Fabre in France, focused primarily on oncology and central nervous system research, and also served as a Deputy Head of Research at Pierre Fabre. Prior to joining Pierre Fabre, Dr Scheer served as a director, global research informatics and knowledge management R&D and project Leader, Neglected Diseases at Merck Serono in Switzerland.